Photosensitization of a subcutaneous tumour by the natural anthraquinone parietin and blue light

MUGAS, MARÍA LAURA; CALVO, GUSTAVO; MARIONI, JULIANA; CÉSPEDES, MARIELA; MARTINEZ, FLORENCIA; VANZULLI, SILVIA; SÁENZ, DANIEL; DI VENOSA, GABRIELA; NUÑEZ MONTOYA, SUSANA; CASAS, ADRIANA

Scientific Reports

Nature Research

Año: 2021 vol. 11 p. 1 - 1

hotodynamic therapy (PDT) is an anticancer treatment involving administration of a tumour-localizing photosensitizer, followed by activation by light of a suitable wavelength. In previous work, we showed that the natural anthraquinone (AQ) Parietin (PTN), was a promising photosensitizer for photodynamic therapy of leukemic cells in vitro. The present work aimed to analyze the photosensitizing ability of PTN in the mammary carcinoma LM2 cells in vitro and in vivo in a model of subcutaneously implanted tumours. Photodynamic therapy mediated by parietin (PTN-PDT) (PTN 30 µM, 1 h and 1.78 J/cm2 of blue light) impaired cell growth and migration of LM2 cells in vitro. PTN per se induced a significant decrease in cell migration, and it was even more marked after illumination (migration index was 0.65 for PTN and 0.30 for PTN-PDT, *p < 0.0001, ANOVA test followed by Tukey’s multiple comparisons test), suggesting that both PTN and PTN-PDT would be potential inhibitors of metastasis. Fluorescen